Literature DB >> 16160152

CD8+ lymphocytes do not mediate protection against acute superinfection 20 days after vaccination with a live attenuated simian immunodeficiency virus.

Richard Stebbings1, Neil Berry, Herman Waldmann, Pru Bird, Geoff Hale, Jim Stott, David North, Robin Hull, Joanna Hall, Jenny Lines, Stuart Brown, Nikki D'Arcy, Leanne Davis, William Elsley, Cherry Edwards, Deborah Ferguson, Jane Allen, Neil Almond.   

Abstract

In order to test the hypothesis that CD8+ cytotoxic T lymphocytes mediate protection against acute superinfection, we depleted >99% of CD8+ lymphocytes in live attenuated simian immunodeficiency virus macC8 (SIVmacC8) vaccinees from the onset of vaccination, maintained that depletion for 20 days, and then challenged with pathogenic, wild-type SIVmacJ5. Vaccinees received 5 mg per kg of humanized anti-CD8 monoclonal antibody (MAb) 1 h before inoculation, followed by the same dose again on days 3, 7, 10, 13, and 17. On day 13, peripheral CD8+ T lymphocytes were >99% depleted in three out of four anti-CD8 MAb-treated vaccinees. At this time attenuated SIVmacC8 viral RNA loads in anti-CD8 MAb-treated vaccinees were significantly higher than control vaccinees treated contemporaneously with nonspecific human immunoglobulin. Lymphoid tissue CD8+ T lymphocyte depletion was >99% in three out of four anti-CD8 MAb-treated vaccinees on the day of wild-type SIVmacJ5 challenge. All four control vaccinees and three out of four anti-CD8 MAb-treated vaccinees were protected against detectable superinfection with wild-type SIVmacJ5. Although superinfection with wild-type SIVmacJ5 was detected at postmortem in a single anti-CD8 MAb-treated vaccinee, this did not correlate with the degree of preceding CD8+ T lymphocyte depletion. Clearance of attenuated SIVmacC8 viremia coincided with recovery of normal CD8+ T lymphocyte counts between days 48 and 76. These results support the view that cytotoxic T lymphocytes are important for host-mediated control of SIV primary viremia but do not indicate a central role in protection against acute superinfection conferred by inoculation with live attenuated SIV.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16160152      PMCID: PMC1211523          DOI: 10.1128/JVI.79.19.12264-12272.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  58 in total

1.  A nonhuman primate model for the selective elimination of CD8+ lymphocytes using a mouse-human chimeric monoclonal antibody.

Authors:  J E Schmitz; M A Simon; M J Kuroda; M A Lifton; M W Ollert; C W Vogel; P Racz; K Tenner-Racz; B J Scallon; M Dalesandro; J Ghrayeb; E P Rieber; V G Sasseville; K A Reimann
Journal:  Am J Pathol       Date:  1999-06       Impact factor: 4.307

Review 2.  Live attenuated AIDS viruses as vaccines: promise or peril?

Authors:  R M Ruprecht
Journal:  Immunol Rev       Date:  1999-08       Impact factor: 12.988

3.  Rapid development of vaccine protection in macaques by live-attenuated simian immunodeficiency virus.

Authors:  C Stahl-Hennig; U Dittmer; T Nisslein; H Petry; E Jurkiewicz; D Fuchs; H Wachter; K Mätz-Rensing; E M Kuhn; F J Kaup; E W Rud; G Hunsmann
Journal:  J Gen Virol       Date:  1996-12       Impact factor: 3.891

4.  Pathogenic conversion of live attenuated simian immunodeficiency virus vaccines is associated with expression of truncated Nef.

Authors:  E T Sawai; M S Hamza; M Ye; K E Shaw; P A Luciw
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

5.  Simian immunodeficiency virus-specific cytotoxic T lymphocytes and protection against challenge in rhesus macaques immunized with a live attenuated simian immunodeficiency virus vaccine.

Authors:  D F Nixon; S M Donahoe; W M Kakimoto; R V Samuel; K J Metzner; A Gettie; T Hanke; P A Marx; R I Connor
Journal:  Virology       Date:  2000-01-05       Impact factor: 3.616

6.  Repair and evolution of nef in vivo modulates simian immunodeficiency virus virulence.

Authors:  A M Whatmore; N Cook; G A Hall; S Sharpe; E W Rud; M P Cranage
Journal:  J Virol       Date:  1995-08       Impact factor: 5.103

7.  Protection by attenuated simian immunodeficiency virus in macaques against challenge with virus-infected cells.

Authors:  N Almond; K Kent; M Cranage; E Rud; B Clarke; E J Stott
Journal:  Lancet       Date:  1995-05-27       Impact factor: 79.321

8.  Passive immune globulin therapy in the SIV/macaque model: early intervention can alter disease profile.

Authors:  N L Haigwood; A Watson; W F Sutton; J McClure; A Lewis; J Ranchalis; B Travis; G Voss; N L Letvin; S L Hu; V M Hirsch; P R Johnson
Journal:  Immunol Lett       Date:  1996-06       Impact factor: 3.685

9.  The development of PCR based assays for the detection and differentiation of simian immunodeficiency virus in vivo.

Authors:  J Rose; P Silvera; B Flanagan; P Kitchin; N Almond
Journal:  J Virol Methods       Date:  1995-02       Impact factor: 2.014

10.  Protection from HIV-1 envelope-bearing chimeric simian immunodeficiency virus (SHIV) in rhesus macaques infected with attenuated SIV: consequences of challenge.

Authors:  W M Bogers; H Niphuis; P ten Haaft; J D Laman; W Koornstra; J L Heeney
Journal:  AIDS       Date:  1995-12       Impact factor: 4.177

View more
  18 in total

1.  CD8+ cell depletion accelerates HIV-1 immunopathology in humanized mice.

Authors:  Santhi Gorantla; Edward Makarov; Jennifer Finke-Dwyer; Catherine L Gebhart; William Domm; Stephen Dewhurst; Howard E Gendelman; Larisa Y Poluektova
Journal:  J Immunol       Date:  2010-05-21       Impact factor: 5.422

2.  Extralymphoid CD8+ T cells resident in tissue from simian immunodeficiency virus SIVmac239{Delta}nef-vaccinated macaques suppress SIVmac239 replication ex vivo.

Authors:  Justin M Greene; Jennifer J Lhost; Benjamin J Burwitz; Melisa L Budde; Caitlin E Macnair; Madelyn K Weiker; Emma Gostick; Thomas C Friedrich; Karl W Broman; David A Price; Shelby L O'Connor; David H O'Connor
Journal:  J Virol       Date:  2010-01-20       Impact factor: 5.103

3.  Immunity and protection by live attenuated HIV/SIV vaccines.

Authors:  Dominik Wodarz
Journal:  Virology       Date:  2008-06-30       Impact factor: 3.616

4.  Persistence of restricted CD4 T cell expansions in SIV-infected macaques resistant to SHIV89.6P superinfection.

Authors:  M-D Salha; R Cheynier; R Halwani; H McGrath; T Y Langaee; B Yassine Diab; J Fournier; M Parenteau; J Edgar; D Ko; A Sherring; D Bogdanovic; R-P Sekaly; E W Rud
Journal:  Virology       Date:  2008-08-01       Impact factor: 3.616

5.  Partial protection of Simian immunodeficiency virus (SIV)-infected rhesus monkeys against superinfection with a heterologous SIV isolate.

Authors:  Wendy W Yeh; Pimkwan Jaru-Ampornpan; Daiva Nevidomskyte; Mohammed Asmal; Srinivas S Rao; Adam P Buzby; David C Montefiori; Bette T Korber; Norman L Letvin
Journal:  J Virol       Date:  2009-01-07       Impact factor: 5.103

6.  Role of Env in resistance of feline immunodeficiency virus (FIV)-infected cats to superinfection by a second FIV strain as determined by using a chimeric virus.

Authors:  Simone Giannecchini; Mauro Pistello; Patrizia Isola; Donatella Matteucci; Paola Mazzetti; Giulia Freer; Mauro Bendinelli
Journal:  J Virol       Date:  2007-07-18       Impact factor: 5.103

Review 7.  Restriction of retroviral replication by APOBEC3G/F and TRIM5alpha.

Authors:  Hendrik Huthoff; Greg J Towers
Journal:  Trends Microbiol       Date:  2008-10-29       Impact factor: 17.079

8.  Ex vivo SIV-specific CD8 T cell responses in heterozygous animals are primarily directed against peptides presented by a single MHC haplotype.

Authors:  Justin M Greene; Emily N Chin; Melisa L Budde; Jennifer J Lhost; Paul J Hines; Benjamin J Burwitz; Karl W Broman; Jennifer E Nelson; Thomas C Friedrich; David H O'Connor
Journal:  PLoS One       Date:  2012-08-22       Impact factor: 3.240

9.  Upregulation of TRIM5α gene expression after live-attenuated simian immunodeficiency virus vaccination in Mauritian cynomolgus macaques, but TRIM5α genotype has no impact on virus acquisition or vaccination outcome.

Authors:  Giada Mattiuzzo; Nicola J Rose; Neil Almond; Greg J Towers; Neil Berry
Journal:  J Gen Virol       Date:  2012-11-14       Impact factor: 3.891

10.  Immunogenicity of a recombinant measles-HIV-1 clade B candidate vaccine.

Authors:  Richard Stebbings; Michèle Février; Bo Li; Clarisse Lorin; Marguerite Koutsoukos; Edward Mee; Nicola Rose; Joanna Hall; Mark Page; Neil Almond; Gerald Voss; Frédéric Tangy
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.